- Global Pharma News & Resources

Antifungal Drugs Market Worth $17.72 Billion by 2023 at 3.7% CAGR, Says AMR

PORTLAND, Oregon, Feb. 19, 2019 /PRNewswire/ -- Allied Market Research published a report, titled, "Antifungal Drugs Market by Drug Type [Echinocandins {Caspofungin, Micafungin, Anidulafungin, and Others}, Azoles {Imidazoles, Voricanazole, Thiazoles, and Others}, Polyenes {Amphotericin B, Candicidin, Hamycin, Natamycin, and Others}, Allylamines {Butenafine, Terbinafine, and Naftifine}, and Others], Infection Type [Superficial Antifungal Infection and Systemic Antifungal Infection], Dosage form [Drugs, Ointment, Powder, and Others] and Therapeutic Indication [Aspergillosis, Dermatophytosis, Candidiasis, and Others] - Global Opportunity Analysis and Industry Forecast, 2017-2023". According to the report, the global antifungal drugs market accounted for $14.23 billion in 2017 and is anticipated to reach $17.72 billion by 2023, growing at a CAGR of 3.7% during the forecast period.

The surge in prevalence of fungal infections worldwide, increase in knowledge of myriad fungal infections among populace, and rise in government funds to tackle antifungal diseases drive the growth of the global antifungal drugs market. Additionally, expiration of existing patents and rise in funding from public & private organizations would provide lucrative opportunities to emerging market players in the near future. However, growth in population that possess antifungal drug resistance and side-effects associated with antifungal drugs hamper market growth.

Request Sample Report at : 

Antifungal drugs to primarily cater the systemic antifungal infections

By infection type, the systemic antifungal segment is expected to maintain its dominant position through 2023 and occupy almost 70% of the global market. This is attributed to their increased demand owing to their bioavailability, efficacy, and enhanced ability to provide better treatment against a broad spectrum of fungi that affects the internal organs severely.

Azoles projected to be the primary drug type in the near future

Based on drug type, azoles is projected to be the largest and fastest growing segment throughout the forecast period, growing at a CAGR of 3.9% to occupy more than one-third of the global market by 2023. Azoles play an active role in the treatment of many fungal infections and the newer versions have evolved to be the first line of defense against myriad fungal infections such as aspergillosis.

Drugs to dominate the global market based on dosage

By dosage form, drugs are not only anticipated to remain the dominant segment in the near future but are also projected to grow at the fastest CAGR of 4.2%. They are expected to generate more than 30% of the global market revenue by 2023, owing to their stability with respect to physical, chemical, and microbiological attributes that help in providing accurate dosage to the patients.

Asia-Pacific to grow at the fastest rate through 2023

Asia-Pacific is expected to register the highest growth rate of 4.5% CAGR throughout the forecast period, owing to the presence of countries with a high populace base, such as India and China, where the antifungal drug usage rate is on a rise due to the growing awareness about fungal infections among the common people and high prevalence of diseases.

For Purchase Enquiry at:

Key market players

The key players analyzed in the report include Pfizer Inc., Sanofi S.A., Gilead Sciences, Inc., Merck & Co., Inc., Novartis International AG, Abbott Laboratories, Bayer AG, Scynexis Inc., Enzon Pharmaceuticals, Inc., and GlaxoSmithKline Plc. They have adopted different strategies including collaborations, joint ventures, partnerships, expansions, mergers & acquisitions, and others to gain a strong position in the industry.

Access KNOWLEDGE TREE (Premium on-demand, subscription-based pricing model) at:

Knowledge tree is a cloud-based intelligence platform that offers more than 2,000 selective, off-the-shelf reports on niche markets to enable our clients gain deep insights on the latest trends, dynamic technologies, and emerging application areas.

Similar Reports:

Drug-Device Combination Products Market - Global Opportunity Analysis & Industry Forecast, 2017-2025

Drug Abuse Testing Market - Global Opportunity Analysis and Industry Forecast, 2018-2025

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975


Editor Details

Last Updated: 19-Feb-2019